10-year outcomes in localized prostate cancer: Authors' reply
We agree with Klotz and Kibel that the lack of significant differences in survival among the three treatments makes a comparison between radiotherapy and surgery unwise. The predetermined power calculation for the ProtecT trial estimated a prostate-cancer mortality rate of 10% at a median of 10 year...
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Journal article |
| Gepubliceerd in: |
Massachusetts Medical Society
2017
|